What type of study is this?

This is a Cohort Study study (also classified as: Human Clinical Trial, Pre-Registered Trial).

What question did this study set out to answer?

To evaluate the efficacy and safety of CD19/CD22 bispecific CAR-T cell therapy in patients with relapsed/refractory large B-cell lymphoma.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Clinical trial demonstrates efficacy and safety of bispecific CAR-T cell therapy in relapsed B-cell lymphoma, indicating a new treatment option.

To evaluate the efficacy and safety of CD19/CD22 bispecific CAR-T cell therapy in patients with relapsed/refractory large B-cell lymphoma.
Ongoing phase 2 clinical trial with 31 patients enrolled
Patients received CAR2219 treatment and underwent 3-day lymphodepletion
Used primary outcomes including overall response rate, complete response rate, progression-free survival, overall survival, and adverse events
Best overall response rate was 100% with 64.5% complete response rate
Median follow-up of 8.1 months; median progression-free survival and overall survival not reached
Common adverse events included neutropenia (93.5%), thrombocytopenia (77%), and cytokine release syndrome (74%)

Liang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Clinical trial demonstrates efficacy and safety of bispecific CAR-T cell therapy in relapsed B-cell lymphoma, indicating a new treatment option.